Burning Rock Biotech Ltd — Director's Dealing 2026

Mar 17, 2026

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Burning Rock Biotech Ltd (BNR)
CIK: 0001792267
Period of Report: 2026-03-17

Reporting Person: Han Yusheng (N/A)

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	17357806	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
OPTIONS (RIGHT TO BUY)	$3.33	2032-09-26	Ordinary Shares (1413063)		Direct
OPTIONS (RIGHT TO BUY)	$3.33	2032-09-26	Ordinary Shares (2119595)		Direct
OPTIONS (RIGHT TO BUY)	$3.33	2032-09-26	Ordinary Shares (706532)		Direct
OPTIONS (RIGHT TO BUY)	$3.33	2032-09-26	Ordinary Shares (1059797)		Direct
OPTIONS (RIGHT TO BUY)	$0.0002	2033-04-30	Ordinary Shares (118012)		Direct
OPTIONS (RIGHT TO BUY)	$0.0002	2033-04-30	Ordinary Shares (86000)		Direct
OPTIONS (RIGHT TO BUY)	$0.0002	2033-04-30	Ordinary Shares (116000)		Direct

Footnotes

F1: On September 26, 2022, the Reporting Person was granted 1,413,063 share options, which will vest once (a) the valuation of the Issuer (based on the 60-day average closing share price of its publicly traded shares) reaches US$4 billion by the seventh anniversary of the date of grant (the "valuation target"), and (b) the Reporting Person remains employed by the Issuer at the time when the valuation target is achieved.

F2: On September 26, 2022, the Reporting Person was granted 2,119,595 share options, which will vest once (a) the valuation of the Issuer (based on the 60-day average closing share price of its publicly traded shares) reaches US$4 billion by the seventh anniversary of the date of grant (the "valuation target"), (b) the Reporting Person remains employed by the Issuer at the time when the valuation target is achieved, and (c) the Reporting Person has been employed by the Issuer for five years from the date of grant.

F3: On September 26, 2022, the Reporting Person was granted 706,532 share options, which will vest once (a) the valuation of the Issuer (based on the 60-day average closing share price of its publicly traded shares) reaches US$10 billion by the seventh anniversary of the date of grant (the "valuation target"), and (b) the Reporting Person remains employed by the Issuer at the time when the valuation target is achieved.

F4: On September 26, 2022, the Reporting Person was granted 1,059,797 share options, which will vest once (a) the valuation of the Issuer (based on the 60-day average closing share price of its publicly traded shares) reaches US$10 billion by the seventh anniversary of the date of grant (the "valuation target"), (b) the Reporting Person remains employed by the Issuer at the time when the valuation target is achieved, and (c) the Reporting Person has been employed by the Issuer for five years from the date of grant.

F5: On April 30, 2023, the Reporting Person was granted 236,023 share options, with 50%, 25% and 25% of the granted share options vesting on January 1, 2025, January 1, 2026 and January 1, 2027, respectively, subject to: (a) the Reporting Person's continued employment, and (b) the annual performance rating of the Reporting Person reaching at least 3.3 for each year from 2023 to 2026.

F6: On April 30, 2024, the Reporting Person was granted 86,000 share options, with 50%, 25% and 25% of the granted share options vesting on January 1, 2026, January 1, 2027 and January 1, 2028, respectively, subject to: (a) the Reporting Person's continued employment, and (b) the annual performance rating of the Reporting Person reaching at least 3.3 for the year of 2024.

F7: On April 30, 2025, the Reporting Person was granted 116,000 share options, with 50%, 25% and 25% of the granted share options vesting on January 1, 2027, January 1, 2028 and January 1, 2029, respectively, subject to: (a) the Reporting Person's continued employment, and (b) the annual performance rating of the Reporting Person reaching at least 3.3 for the year of 2025.

F8: Each share option represents the right to receive, upon exercise, one ordinary share.